『FDA Approves Outlook's Lytenava for Wet AMD』のカバーアート

FDA Approves Outlook's Lytenava for Wet AMD

FDA Approves Outlook's Lytenava for Wet AMD

無料で聴く

ポッドキャストの詳細を見る
The CEO of Outlook Therapeutics discusses the FDA approval of wet AMD drug Lytenava; Roche receives a major boost in its efforts to commercialize wet AMD treatment Susvimo in Europe; and Glaukos reaches a milestone in its pivotal clinical study of the Preserflo MicroShunt. Learn more about your ad choices. Visit megaphone.fm/adchoices
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません